This study reveals a high level of behavioral heterogeneity in engineered T cells that target tumor organoids. Behavior-guided transcriptomics identified the gene signatures of T cells with highly potent serial cytotoxicity. Integration of the organoid and T cell transcriptomic data enabled the design of patient-specific combinatorial treatment to achieve an optimized response to cancer immunotherapies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017). A report on the limitations of immunotherapy for solid tumors.
Hegde, P. S. & Chen, D. S. Top 10 challenges in cancer immunotherapy. Immunity 52, 17–35 (2019). A Perspective article that presents the current challenges in optimization of cancer immunotherapy.
Tuveson, D. & Clevers, H. Cancer modeling meets human organoid technology. Science 364, 952–955 (2019). A Review discussing the use of organoids as tumor models that recapitulate the original tumor characteristics.
Ganesh, K. et al. A rectal cancer organoid platform to study individual responses to chemoradiation. Nat. Med. 25, 1607–1614 (2019). A research article showing the potential of organoids for personalized treatment.
Crainiciuc, G. et al. Behavioural immune landscapes of inflammation. Nature 601, 415–421 (2022). A research article that demonstrates how behavioral profiling can be used to infer immune cell function.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Dekkers, J. F. et al. Uncovering the mode of action of engineered T cells in patient cancer organoids. Nat. Biotechnol. https://doi.org/10.1038/s41587-022-01397-w (2022).
Rights and permissions
About this article
Cite this article
BEHAV3D: an imaging and transcriptomics platform that unravels T cell antitumor activity. Nat Biotechnol 41, 31–32 (2023). https://doi.org/10.1038/s41587-022-01398-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-022-01398-9
